Tuberculosis remains a major public-health challenge in India, where timely detection must work across tertiary hospitals, district facilities, mobile screening units, and primary-care networks. Radiology TB detection is especially valuable for pulmonary screening because chest imaging is fast, scalable, and increasingly compatible with artificial-intelligence tools. It is not, however, a substitute for microbiological confirmation or clinical assessment.
A useful TB pathway combines symptoms, exposure and risk history, chest imaging, and tests such as rapid molecular assays. Imaging helps identify people who need prompt evaluation; laboratory testing determines whether *Mycobacterium tuberculosis* is present and whether drug resistance may affect treatment.
What radiology can and cannot establish
Chest radiology can reveal patterns associated with active pulmonary TB, including upper-lobe opacities, cavities, nodules, consolidation, fibrosis, pleural disease, and lymph-node enlargement. These findings can also occur in bacterial pneumonia, fungal infection, malignancy, sarcoidosis, and healed TB. A normal chest X-ray reduces the likelihood of pulmonary disease but does not rule it out in every patient, particularly those who are immunocompromised or have early disease.
Radiology is most useful when it answers a practical question: who should receive confirmatory testing and urgent clinical review? It can also help assess complications, distinguish active-looking disease from old scarring, and identify extrapulmonary involvement that requires a different imaging strategy.
Main imaging options for TB detection
Chest X-ray: the frontline tool
Digital chest X-ray is generally the first imaging test for suspected pulmonary TB because it is comparatively inexpensive, rapid, and available in many Indian hospitals and screening programmes. Portable units can extend access to remote communities, prisons, shelters, mines, and other high-risk settings.
A radiologist or trained clinician may assess the image for cavities, infiltrates, miliary patterns, pleural effusion, and hilar or mediastinal changes. The report should describe the finding and recommend the next step rather than simply label an image “TB” or “not TB.” For example, a suspicious result should trigger sputum collection or another appropriate molecular test.
CT: problem-solving, not routine screening
Computed tomography provides greater anatomical detail and can identify small cavities, tree-in-bud nodules, lymphadenopathy, bronchiectasis, and complications that are difficult to characterise on X-ray. It is useful when symptoms and X-ray findings disagree, when disease is complicated, or when clinicians must investigate an alternative diagnosis.
CT involves more radiation and expense, and scanner access is uneven outside major centres. It should therefore be used selectively, with attention to pregnancy, paediatric imaging, renal function when contrast is planned, and the principle of keeping exposure as low as reasonably achievable.
MRI, ultrasound and PET-CT
MRI has a limited role in lung imaging but is valuable for suspected TB of the brain, spine, joints, and soft tissues. Contrast-enhanced MRI may help evaluate tuberculomas, meningitis-related complications, or spinal cord compression. Ultrasound can support assessment of pleural fluid, abdominal disease, lymph nodes, and accessible collections.
PET-CT can demonstrate metabolically active lesions and assist in complex cases, treatment-response assessment, or differentiating disease sites. Its cost, radiation burden, and limited availability make it unsuitable for population-level screening.
AI-assisted radiology TB detection
AI software can analyse chest X-rays and assign a probability of TB-like abnormality, helping prioritise confirmatory testing and radiologist review. This is particularly useful where reporting capacity is limited. AI may also support triage in high-volume screening campaigns and integrate with portable digital X-ray devices.
However, performance depends on the population, equipment, image quality, disease prevalence, and threshold selected. A model trained largely on one geography may perform differently in Indian patients, children, people living with HIV, or those with prior lung disease. Health systems should validate tools locally, monitor sensitivity and false-negative rates, and maintain a clear human escalation pathway. The practical principles described in AI for Early Disease Detection in India apply directly to dataset quality, clinical validation, and deployment governance.
AI should produce an auditable recommendation, not an unexplained diagnosis. Procurement teams should ask about regulatory status, external validation, cybersecurity, data storage, calibration, language and workflow support, and how the system behaves when images are poor or incomplete.
A practical diagnostic workflow in India
A workable pathway can follow these steps:
- Identify risk and symptoms: Ask about cough, fever, weight loss, night sweats, exposure, previous TB, HIV, diabetes, silicosis, malnutrition, and immunosuppression.
- Capture a quality image: Use an appropriate digital chest X-ray protocol, correct positioning, and repeat technically inadequate studies when clinically justified.
- Triage the image: A trained reader or validated AI tool can prioritise suspicious cases; AI output should not replace clinical responsibility.
- Collect confirmatory samples: Use sputum or another suitable specimen for rapid molecular testing, culture, and drug-susceptibility assessment according to the clinical situation.
- Escalate complex cases: Use CT, MRI, ultrasound, or specialist referral when extrapulmonary disease, complications, or diagnostic uncertainty is present.
- Close the loop: Record results, notify the treating team, start appropriate care, and arrange contact evaluation and follow-up.
This workflow is strongest when imaging, laboratory services, and public-health reporting share interoperable records. Automated reporting can reduce administrative delays; see Automated Radiology Reporting Using Deep Learning for considerations around structured reports, review queues, and deployment in Indian hospitals.
Implementation challenges and safeguards
The biggest barriers are not only algorithmic. Facilities may face unreliable power, limited internet connectivity, poor image archiving, inadequate maintenance, and shortages of radiographers and radiologists. Rural programmes also need referral protocols, sample transport, infection-control procedures, and mechanisms for returning results to patients.
A TB imaging programme should track operational metrics such as time from image acquisition to review, time to molecular confirmation, proportion of unreadable images, missed cases, false-positive referrals, and treatment initiation. It should also protect patient privacy through role-based access, encryption, consent practices, retention policies, and de-identification for model development.
For builders, the opportunity is to design for constrained environments: offline-first inference, low-bandwidth synchronisation, explainable flags, multilingual interfaces, device calibration checks, and dashboards that connect screening teams to diagnostic laboratories. These principles overlap with Efficient Real-Time Object Detection on Low-Power Hardware, although medical systems require much stricter validation and clinical oversight.
What patients should know
A suspicious X-ray does not prove TB, and a reassuring image does not always exclude it. Patients should complete the recommended molecular or other laboratory testing, disclose previous TB treatment, and report worsening breathlessness, coughing blood, severe weakness, or neurological symptoms urgently. People with possible infectious pulmonary TB should follow local clinical advice on masks, ventilation, and limiting close exposure until assessed.
The path forward
By 2026, the most useful TB imaging systems are not standalone AI products. They are complete care pathways that connect portable imaging, calibrated AI triage, expert review, molecular confirmation, referral, and follow-up. India’s priority should be equitable deployment: validate tools on representative local data, strengthen district-level infrastructure, and measure whether technology shortens time to diagnosis and treatment.
For organisations developing solutions in this space, AI Grants India can be a starting point for exploring support for responsible, high-impact healthcare innovation. The strongest proposals will show clinical partners, a validation plan, measurable public-health outcomes, and a realistic route from pilot to routine care.